- Home
- FLGT vs PRAX Comparison
FLGT vs PRAX Comparison
Compare FLGT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGT
- PRAX
- Stock Information
- Founded
- FLGT 2011
- PRAX 2015
- Country
- FLGT United States
- PRAX United States
- Employees
- FLGT N/A
- PRAX N/A
- Industry
- FLGT Medical Specialities
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- FLGT Health Care
- PRAX Health Care
- Exchange
- FLGT Nasdaq
- PRAX Nasdaq
- Market Cap
- FLGT 639.0M
- PRAX 599.7M
- IPO Year
- FLGT 2016
- PRAX 2020
- Fundamental
- Price
- FLGT $19.53
- PRAX $42.34
- Analyst Decision
- FLGT Buy
- PRAX Strong Buy
- Analyst Count
- FLGT 2
- PRAX 11
- Target Price
- FLGT $24.00
- PRAX $114.73
- AVG Volume (30 Days)
- FLGT 256.3K
- PRAX 294.2K
- Earning Date
- FLGT 08-01-2025
- PRAX 08-12-2025
- Dividend Yield
- FLGT N/A
- PRAX N/A
- EPS Growth
- FLGT N/A
- PRAX N/A
- EPS
- FLGT N/A
- PRAX N/A
- Revenue
- FLGT $292,448,000.00
- PRAX $8,122,000.00
- Revenue This Year
- FLGT $11.79
- PRAX N/A
- Revenue Next Year
- FLGT $10.45
- PRAX $6,358.50
- P/E Ratio
- FLGT N/A
- PRAX N/A
- Revenue Growth
- FLGT 1.71
- PRAX 270.02
- 52 Week Low
- FLGT $14.57
- PRAX $26.70
- 52 Week High
- FLGT $25.11
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- FLGT 40.94
- PRAX 54.36
- Support Level
- FLGT $20.30
- PRAX $41.64
- Resistance Level
- FLGT $21.07
- PRAX $44.99
- Average True Range (ATR)
- FLGT 0.69
- PRAX 2.55
- MACD
- FLGT -0.25
- PRAX -0.11
- Stochastic Oscillator
- FLGT 1.15
- PRAX 51.07
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.